Tildrakizumab for Moderate-to-Severe Chronic Plaque Psoriasis: a Review of the Literature

被引:0
作者
Kory P. Schrom
Avi Bitterman
Neil J. Korman
机构
[1] University Hospitals Cleveland Medical Center,Department of Dermatology
[2] Case Western Reserve University,Department of Dermatology
来源
Current Dermatology Reports | 2019年 / 8卷
关键词
Tildrakizumab; Interleukin 23; Psoriasis; Review; Efficacy; Safety;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:6 / 13
页数:7
相关论文
共 267 条
[1]  
Helmick CG(2014)Prevalence of psoriasis among adults in the U.S.: 2003-2006 and 2009-2010 National Health and Nutrition Examination Surveys Am J Prev Med 47 37-45
[2]  
Lee-Han H(1997)The economic impact of psoriasis increases with psoriasis severity J Am Acad Dermatol 37 564-569
[3]  
Hirsch SC(2015)Psoriasis: classical and emerging comorbidities An Bras Dermatol 90 9-20
[4]  
Baird TL(2008)Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics J Am Acad Dermatol 58 826-850
[5]  
Bartlett CL(2015)The immunopathogenesis of psoriasis Dermatol Clin 33 13-23
[6]  
Feldman SR(2018)Tildrakizumab-asmn: what’s in a name? Am J Clin Dermatol 19 291-292
[7]  
Fleischer AB(2017)The role of IL 23 in the treatment of psoriasis Expert Rev Clin Immunol 13 525-534
[8]  
Reboussin DM(2017)The role of IL-23 and the IL-23/T J Eur Acad Dermatol Venereol 31 1616-1626
[9]  
Rapp SR(1998) 17 immune axis in the pathogenesis and treatment of psoriasis J Invest Dermatol 111 1053-1057
[10]  
Bradham DD(2000)Expression of interleukin-12 is increased in psoriatic skin Immunity 13 715-725